Company Long-Term Loans and Borrowings: matinasbiopharma.com (MTNB)

The price history of Matinas BioPharma (MTNB) demonstrates the asset's dependence on venture capital inflows, as real operational cash flow has not yet been generated. Business revenues rely on the market launch of drug delivery systems, including innovative LNC-based oral forms. Meanwhile, the company's environmental profile is improving through the implementation of "green chemistry," and the metric stands at 0.00.

This indicator captures total creditor obligations with a maturity of more than one year, reflecting the inertia of the debt load. The metric measures financial leverage, where rising borrowings amid increasing interest rates create a risk of declining capitalization. For Matinas BioPharma (MTNB), the debt strategy is limited to patent licensing to fund R&D. Avoiding mergers minimizes the probability of sharp spikes in debt. By analyzing the company's long-term debt history, an investor assesses the sustainability of its organic growth.